DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for interdigitating dendritic cell sarcoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInterdigitating dendritic cell sarcoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for interdigitating dendritic cell sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
B-Raf proto-oncogene, serine/threonine kinase (BRAF) — BRAF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet agsdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8VYP · 3.29 Å · ligand PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER (AGS). Experimental structure, not a prediction.
What the evidence adds up to
Interdigitating dendritic cell sarcoma is an extremely rare cancer for which no standard treatment exists. A 2010 report describes one patient who was surgically resected and remained disease-free; the tumour was assessed by immunohistochemical staining for druggable targets that could be used if the disease recurred. A 2015 case describes a 39-year-old patient with a primary intracranial interdigitating dendritic cell sarcoma who underwent complete resection of a large parafalx tumour and recovered fully from right hemiparesis. After 1.5 years that patient remained recurrence-free under close observation. The authors state that based on limited experience with extracranial occurrence, the tumour is best managed by complete resection and careful oncological observation.
No abstract in this set reports any drug treatment or systemic therapy for interdigitating dendritic cell sarcoma. The 2010 paper mentions assessing the tumour for druggable targets but gives no results of that assessment and no subsequent treatment. The 2001 paper discusses soft tissue sarcoma generally as a model for cancer immunotherapy, noting that many sarcomas contain tumour-specific chromosomal translocations encoding fusion proteins that are attractive targets. The 2013 review argues that immunotherapy is emerging as a plausible modality for sarcoma because of advances in other cancers, but it does not present data for interdigitating dendritic cell sarcoma specifically. The 2012 paper describes dendritic cell immunotherapy in soft tissue sarcoma, reporting that in animal models and human trials dendritic cells have induced an antitumour immune response, and that hypofractionated radiotherapy before excision may potentiate that effect, but again no data for this specific sarcoma subtype are given.
What is missing is any clinical trial testing a drug or immunotherapy in interdigitating dendritic cell sarcoma, any patient stratification strategy, and any funding to make such a trial possible. The published evidence consists of two single-patient surgical reports and general reviews of sarcoma immunotherapy that do not address this particular disease. Without a trial, no conclusion about drug efficacy can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2001 · 29 citations
Soft tissue sarcoma as a model disease to examine cancer immunotherapy
AbstractImmunotherapy is in its infancy for many diseases, whether they are neoplastic or autoimmune. The major issues for cancer immunotherapy today involve the definition of molecular targets and the generation of effector mechanisms to attack the targets of interest. Soft tissue sarcomas provide a unique opportunity to examine the immune response against defined antigens. Many types of sarcomas contain tumor-specific chromosomal translocations encoding fusion proteins, which are attractive targets for immunotherapy. Our understanding of the immune system is also coming into clearer focus with the discovery of dendritic cells as powerful natural adjuvants and the teasing out of mechanisms leading to immunity versus tolerance as examples. It is hoped that the intersection of cellular immunology and sarcoma molecular biology will lead to new modalities of therapy for this group of patients with this heterogeneous group of diseases.
AbstractBACKGROUND AND IMPORTANCE: This is the first report of a primarily intracranial interdigitating dendritic cell sarcoma (IDCS). CLINICAL PRESENTATION: A 39-year-old patient with right hemiparesis underwent complete resection of a large parafalcine tumor with subsequent complete recovery of neurological symptoms. Histologically, the tumor was diagnosed as IDCS. Extensive staging did not reveal any extracranial manifestation of this disease. After 1.5 years, the patient remains recurrence free and is being observed closely. CONCLUSION: IDCS are exceedingly rare tumors and so far have not been found intracranially. On the basis of the limited experience with extracranial occurrence, this tumor is best managed by complete resection and careful oncological observation. ABBREVIATIONS: FDCS, follicular dendritic cell sarcomaIDCS, interdigitating dendritic cell sarcomaRTU, ready-to-use kit.
Molecular characterization of interdigitating dendritic cell sarcoma
AbstractInterdigitating dendritic cell sarcoma is an extremely rare cancer that lacks a standard treatment approach. We report on a patient who was surgically resected and remains disease- free. The tumor was assessed for druggable targets using immunohistochemical staining to identify potential agents that could be used in the event of disease recurrence.
AbstractPURPOSE OF REVIEW: To describe the current advances in immunotherapy and how they can be applied to sarcoma. This review will discuss the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma will be reviewed, as will the potential incorporation of immunotherapy into treatment for sarcoma. RECENT FINDINGS: Sarcoma, cancer of the connective tissues, frequently strikes young people, comprising a large percentage of cancer in children and young adults, but may occur at any age. Although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. SUMMARY: Sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that our knowledge of the immune system has reached the point where it can be used to augment both targeted and multimodality therapy for sarcoma.
Dendritic Cell Immunotherapy in Soft Tissue Sarcoma
AbstractSoft tissue sarcomas represent a rare but diverse family of tumors affecting patients of all ages. Conventional chemotherapy rarely eradicates metastatic disease and newer targeted agents are successful in only very specific histologic subgroups. Therefore, scientists and clinicians are investigating immunotherapy techniques, primarily involving cellular immunity focused on the T-cell response to tumor antigens. In both animal models and human sarcoma trials, dendritic cells have been shown to induce an effective antitumor immune response. Radiotherapy, particularly when delivered in a hypofractionated manner prior to sarcoma excision, may potentiate the function of the dendritic cells through the induction of apoptosis. The synergistic effect may carry over to other cancer types and warrants further multidisciplinary investigation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
